Lowering triglycerides interventions
Pro Research Analysisby 
Searched over 200M research papers
Triglyceride Lowering Interventions: Overview and Clinical Impact
Lowering triglycerides (TG) is an important strategy for reducing cardiovascular risk, especially in patients with diabetes or a history of cardiovascular disease. Multiple interventions, both established and emerging, have been studied for their effectiveness in lowering TG and improving cardiovascular outcomes.
Established Triglyceride-Lowering Therapies
Statins, Fibrates, and Niacin
Statins are widely used for lipid lowering and have a modest effect on triglycerides, but their primary benefit is in lowering LDL cholesterol. Fibrates and niacin are more effective at lowering TG, but large clinical trials have shown inconsistent results regarding their ability to reduce cardiovascular events, especially when used alongside statins. Some benefit has been observed in patients with high TG and low HDL, a common pattern in diabetes, but overall evidence is mixed 2567+1 MORE.
Omega-3 Fatty Acids
Prescription omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have shown significant TG-lowering effects. The REDUCE-IT trial demonstrated that icosapent ethyl (a purified EPA) reduced TG by about 20% and led to a 25% reduction in major cardiovascular events in high-risk patients already on statins. This benefit appears to be specific to high-dose EPA, as other omega-3 formulations (including those with docosahexaenoic acid, DHA) have not consistently shown similar cardiovascular benefits 2578+1 MORE.
New and Emerging Triglyceride-Lowering Interventions
RNA-Based and Monoclonal Antibody Therapies
Recent advances have led to the development of therapies targeting specific proteins involved in TG metabolism, such as apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3). Antisense oligonucleotides and monoclonal antibodies against these targets have shown promising TG-lowering effects in early studies, and ongoing trials are evaluating their impact on cardiovascular outcomes 178.
Pemafibrate
Pemafibrate, a selective PPARα modulator, significantly lowers TG and other atherogenic lipids. However, the PROMINENT trial found that despite substantial TG reduction, pemafibrate did not lower the incidence of cardiovascular events in patients with diabetes and mild-to-moderate hypertriglyceridemia .
Novel Small Molecules
Experimental compounds, such as tricyclic matrine derivatives, have shown potent TG-lowering effects in preclinical models of non-alcoholic fatty liver disease (NAFLD), suggesting potential for future drug development .
Lifestyle Modifications
Lifestyle changes, including dietary adjustments, weight loss, and increased physical activity, remain the first-line approach for managing elevated TG. These interventions are effective, safe, and recommended for all patients with hypertriglyceridemia .
Clinical Outcomes and Considerations
Meta-analyses and systematic reviews indicate that TG-lowering therapy is associated with a modest reduction in cardiovascular events and cardiovascular-specific mortality, particularly in high-risk populations such as those with diabetes. However, the benefit is less clear for stroke and all-cause mortality, and not all TG-lowering drugs have demonstrated cardiovascular benefit in clinical trials 2567+2 MORE.
Conclusion
Lowering triglycerides can reduce cardiovascular risk, especially in high-risk patients with diabetes or persistent hypertriglyceridemia despite statin therapy. High-dose EPA (icosapent ethyl) is currently the most evidence-based pharmacological option for reducing both TG and cardiovascular events. New therapies targeting TG metabolism are promising but require further study. Lifestyle modification remains essential for all patients with elevated TG.
Sources and full results
Most relevant research papers on this topic